| Service |
Features |
Specialist |
| Nuclear medicine imaging |
We offer a wide variety of high-quality nuclear medicine imaging including bone scan, myocardial perfusion imaging, dynamic cardiac SPECT, renal scan, lung scan, brain perfusion SPECT, thyroid and parathyroid scan, inflammation scan, etc. |
Shen, Hueng-Yuan
Lin, Chang-Chung
Hu, Chin
Chiu, Yu-Li
Chan, Hung-Pin |
| Positron emission tomography |
We can obtain various PET imaging agents for clinical diagnosis and research purposes, including
- F-18 FDG be applied in oncology, cardiology and neurology.
- F-18 Fluciclovine and F-18 PSMA for the assessment of prostate cancer.
- F-18 Amyloid for the assessment of Alzheimer's disease.
- F-18 NaF for the assessment bone metastasis.
|
Shen, Hueng-Yuan
Lin, Chang-Chung
Hu, Chin
Chiu, Yu-Li
Chan, Hung-Pin |
| Radioimmunoassay |
Our radioimmunoassay (RIA) laboratory perform more than 100,000 variable medical testing per year including hormones (such as thyroid hormones, sex hormones, insulin, growth hormone, etc.), trace proteins, tumor markers (such as AFP, CEA, PSA, CA-125, CA-199, CA-153, etc.) and drugs (such as Digoxin, etc.) |
Lin, Chang-Chung Hu, Chin |
| Radiopharmaceutical treatment |
We have the newest, sophisticated designed radioisotope treatment center equipped with intelligent patient monitoring, radiation measuring and management systems, providing in-hospital and outpatient radioisotope treatment. The treatment we provide include and not limited to
- I-131 treatment for benign and malignant thyroid disease.
- Y-90 microspheres SIRT for primary and metastatic liver cancer.
- Ra-223 treatment for metastatic bone disease.
- Lu-177 PSMA for prostate cancer theranostics.
- Lu-177 DOTATATE for neuroendocrine tumor theranostics.
|
Shen, Hueng-Yuan
Chiu, Yu-Li
Chan, Hung-Pin |
| Precision medicine and re-differentiation therapy of thyroid cancer |
- Precision medicine is suitable for the treatment of thyroid cancer (1) pre-surgery assessment, (2) re-use of radioactive iodine after recurrence, and (3) selection of target drugs, among which the selection of target drugs for advanced cancer is more popular.
- The efficacy of radioactive iodine therapy can be predicted. In cases where it may be ineffective, "redifferentiation drugs" can be used in advance to enhance the effect of radioactive iodine therapy. Usually when the recurrent tumor is unresectable or has distant metastasis, when considering radioactive iodine therapy, relevant genetic testing can be performed first to analyze whether specific drugs that can reverse the abnormal genes or molecular biology can be used in conjunction with radioactive iodine therapy to achieve the enhanced effect of radioactive iodine in killing cancer cells.
|
Shen, Hueng-Yuan
|